Octahydro-pyrrolo[3,4-b]pyrrole derivatives

Details Octahydro-pyrrolo[3,4-b]pyrrole derivatives Octahydro-pyrrolo[3,4-b]pyrrole derivatives

2007-02-13

2010-06-01

Shameem, Golam M (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S224000, C544S239000, C544S358000, C544S359000, C548S452000, C548S453000, C514S412000, C514S252130

Reexamination Certificate

active

07728031

ABSTRACT:
Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands, Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.

REFERENCES:
patent: 5071999 (1991-12-01), Schenke et al.
patent: 7462599 (2008-12-01), Schilling et al.
patent: 2004/0092521 (2004-05-01), Altenbach et al.
patent: 2005/0101602 (2005-05-01), Basha et al.
patent: 2005/0245543 (2005-11-01), Howard et al.
patent: 2006/0019998 (2006-01-01), Wager et al.
patent: 2008/0221093 (2008-09-01), Gege et al.
patent: 32 31 088 (1983-03-01), None
patent: 0393424 (1995-09-01), None
patent: 0350733 (1997-08-01), None
patent: 9635691 (1996-11-01), None
patent: 0024719 (2000-05-01), None
patent: 01/66534 (2001-09-01), None
patent: WO 01/81347 (2001-11-01), None
patent: 0206223 (2002-01-01), None
patent: 0206278 (2002-01-01), None
patent: 0240461 (2002-05-01), None
patent: 02070523 (2002-09-01), None
patent: 02072093 (2002-09-01), None
patent: 2004092173 (2004-10-01), None
patent: 2004097408 (2004-11-01), None
patent: 2005/054194 (2005-06-01), None
patent: 2005056056 (2005-06-01), None
patent: 2005075479 (2005-08-01), None
patent: 2006/018280 (2006-02-01), None
patent: 2007007069 (2007-01-01), None
patent: 2007027734 (2007-03-01), None
patent: 2007093363 (2007-08-01), None
patent: 2007093364 (2007-08-01), None
patent: 2007100990 (2007-09-01), None
patent: 2007110868 (2007-10-01), None
patent: 2008005338 (2008-01-01), None
patent: 2008014240 (2008-01-01), None
patent: 2008023239 (2008-02-01), None
patent: 2008024978 (2008-02-01), None
patent: 2008041090 (2008-04-01), None
patent: 2008059238 (2008-05-01), None
patent: 2008153958 (2008-12-01), None
patent: 2009036132 (2009-03-01), None
Aranyos, A., et al., “Novel Electron-Rich Bulky Phosphine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Esthers”, Journal of American Chemical Society, vol. 121, pp. 4369-4378, 1999.
Arrang, J.-M., et al., “Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor”, Nature, vol. 302, pp. 832-837, 1983.
Arrang, J.-M., et al., “Highly potent and selective ligands for histamine H3-receptors”, Nature, vol. 327, pp. 117-123, 1987.
Barbier, A.J., et al., “Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist”, British Journal of Pharmacology, vol. 143, pp. 649-661, 2004.
Bates, R., et al., “High-Yield Benzyne Synthesis of Diary 1 Ethers”, Journal of Organic Chemistry, vol. 47, pp. 4374-4376, 1982.
Bernaerts, P., et al., “Histamine H3 antagonist thioperamide dose-dependently enhances memory consolidation and reverses amnesia induced by dizocilpine or scopolamine in a one-trial inhibitory avoidance task in mice”, Behavioural Brain Research, vol. 154, pp. 211-219, 2004.
Bjenning, C., et al., “Peripherally administered ciproxifan elevates hypothalamic histamine levels and potently reduces food intake in the Sprague Dawley rat”, Abstracts, International Sendai Histamine Symposium, Sendai, Japan, #P39, pp. 449-452, Nov. 2000.
Black, W.C., et al., “2, 3-Diarylcyclopentenones as Orally Active, Highly Selective Cyclooxygenase-2 Inhibitors”, Journal of Medicinal Chemistry, vol. 42, p. 1274-1281, 1999.
Browman, K.E., et al., “Enhancement of prepulse inhibition of startle in mice by the 1-β receptor antagonists thioperamide and ciproxifan”, Behavioural Brain Research, vol. 153, No. 1, pp. 69-76, 2004.
Burns, et al., “PET ligands for assessing receptor occupancy in vivo”, Annual Reports in Medicinal Chemistry, vol. 36, pp. 267-276, 2001.
Burns, et al., “Positron emission tomography neuroreceptor imaging as a tool in drug discovery, research and development”, Current Opinion in Chemical Biology, vol. 3, No. 4, pp. 388-394, 1999.
Carroll, F.I., et al., “Synthesis, Nicotinic Acetylcholine Receptor Binding, and Antinociceptive Properties of 2-exo-2-(2¢-Substituted 5¢-pyridiny1)-7-azabicyclo[2.2.1]heptanes. Epibatidine Analogues”, Journal of Medicinal Chemistry, pp. 2229-2237, 2001.
Chávez, et al., “Histamine (H3) receptors modulate the excitatory amino acid receptor response of the vestibular afferents”, Brain Resarch, vol. 1064, pp. 1-9, 2005.
Chen, et al., “Effects of histamine on MK-801-induced memory deficits in radial maze performance in rats”, Brain Research, vol. 839, pp. 186-189, 1999.
Chen, Z., et al., “Pharmacological effects of carcinine on histaminergic neurons in the brain”, British Journal of Pharmacology, vol. 143, pp. 573-580, 2004.
Clapham, J., et al., “Thioperamide, the selective histamine H3 receptor antagonist, attenuates stimulant induced locomotor activity in the mouse”, European Journal of Pharmacology, vol. 259, No. 2, pp. 107-114, 1994.
Cowart, et al., “4-(2-[2-(2(R)-Methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and Related 2-Aminoethylbenzofuran H3 Receptor Antagonists Potently Enhance Cognition and Attention”, Journal of Medicinal Chemistry, vol. 48, pp. 38-55, 2005.
de Almeida, et al., “Memory Facilitation by Histamine”, Archives of Int Pharmacodyn, vol. 283, pp. 193-198, 1986.
Delaunois, A.A., et al., “Modulation of acetylcholine, capsaicin and substance Peffects by histamine H 3 receptors in isolated perfused rabbit lunge”, European Journal of Pharmacology, vol. 277, pp. 243-250, 1995.
Dimitriadou, et al., “Functional relationship between mast cells and C-sensitive nerve fibres evidenced by histamine H3-receptor modulation in rat lung and spleen”, Clinical Science, vol. 87, pp. 151-163, 1994.
Duméry, V., et al., “Development of amygdaloid cholinergic mediation of passive avoidance learning in the rat”, Experimental Brain Research, vol. 67, pp. 61-69, 1987.
Dvorak, C., et al., “4-Phenoxypiperidines: Potent, Conformationally, Restricted, Non-Imidazole Histamine H3 Antagonists”, Journal of Medicinal Chemistry, vol. 48, pp. 2229-2238, 2005.
Esbenshade, T.A., et al., “Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethy1}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties”, Journal of Pharmacology and Experimental Therapeutics, vol. 313, pp. 165-175, 2005.
Esbenshade, T.A., et al., “Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist”, Biochemical Pharmacology, vol. 68, pp. 933-945, 2004.
Fitzsimons, C.H., et al., “Histamine receptors signaling in epidermal tumor cell lines with H-ras gene alterations”, Inflammation Research, vol. 47 (Suppl. 1), pp. S50-S51, 1998.
Fox, G.B., et al., “Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup”, Behavioural Brain Research, vol. 131, pp. 151-161, 2002.
Fox, G.B., et al., “Two Novel and Selective Nonimidazole H3 Receptor Antagonists A-304121 and A-317920: II. In Vivo Behavioral and Neurophysiological Characterization”, Journal of Pharmacology and Experimental Therapeutics, vol. 305, pp. 897-908, 2003.
Fox, G.B., “Identification of novel H3 receptor (H3R) antagonists with cognition enhancing properties in rats”, Inflammation Research, vol. 52, pp. S31-S32, 2003.
Fox, G.B., et al., “Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist”, Journal of Pharmacology and Experimental Therapeutics, vol. 313, No. 1, pp. 176-190, 2005.
Fu

Affiliated with

Also associated with

Rating

Octahydro-pyrrolo[3,4-b]pyrrole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Octahydro-pyrrolo[3,4-b]pyrrole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Octahydro-pyrrolo[3,4-b]pyrrole derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4170404